A Brief History of CureVac N.V. (CVAC)

Founded in 2000, CureVac N.V. is a German biopharmaceutical company that focuses on the development of mRNA-based vaccines and therapeutics. The company was established by Ingmar Hoerr, Steve Pascolo, and Florian von der Mülbe, with the goal of utilizing messenger RNA (mRNA) technology for various medical applications.

One of the key milestones for CureVac was the development of a novel mRNA-based technology platform that enables the company to rapidly produce vaccines and therapeutics for a wide range of diseases. This platform has proven to be highly versatile and effective, leading to several successful preclinical and clinical studies.

• In 2011, CureVac entered into a collaboration with Boehringer Ingelheim to develop a mRNA-based vaccine for lung cancer.
• In 2015, the company received a significant investment from the Bill & Melinda Gates Foundation to support the development of vaccines for infectious diseases.
• In 2020, CureVac gained international attention for its efforts to develop a mRNA-based vaccine for COVID-19, which showed promising results in early clinical trials.

Today, CureVac continues to be at the forefront of mRNA technology, with a strong pipeline of potential vaccines and therapies for a variety of diseases. The company went public on the Nasdaq in August 2020 under the ticker symbol CVAC, further solidifying its position as a leader in the field of mRNA-based medicine.

Who Owns CureVac N.V. (CVAC)

CureVac N.V. (CVAC) is a biopharmaceutical company that is publicly traded on the NASDAQ stock exchange. As a publicly traded company, CureVac N.V. is owned by a combination of individual and institutional investors who hold shares of the company's stock.

Some of the major institutional investors that own significant stakes in CureVac N.V. include:

• Dievini Hopp Biotech Holding: A major shareholder in CureVac, Dievini Hopp Biotech Holding is the investment vehicle of Dietmar Hopp, co-founder of SAP and one of the richest individuals in Germany.
• Gates Foundation: The Bill and Melinda Gates Foundation, founded by billionaire philanthropists Bill and Melinda Gates, also holds a stake in CureVac N.V.
• Baillie Gifford & Co: This Scottish investment firm is known for its long-term, high-conviction investment approach and is a significant investor in CureVac N.V.

In addition to institutional investors, individual investors also own shares of CureVac N.V. These individual investors can include retail investors, high net-worth individuals, and company executives.

Overall, the ownership of CureVac N.V. is diverse, with a mix of institutional and individual investors holding stakes in the company.

CureVac N.V. (CVAC) Mission Statement

CureVac N.V. is a biopharmaceutical company dedicated to harnessing the power of mRNA technology to develop innovative vaccines and therapies for a range of diseases.

Our mission is to improve global health by advancing the field of mRNA-based pharmaceuticals, with a focus on preventing and treating infectious diseases, cancer, and rare genetic disorders.

We are committed to developing safe, effective, and affordable mRNA-based vaccines and therapies that have the potential to transform healthcare and save lives around the world.

Our core values of innovation, integrity, and collaboration guide everything we do as we strive to make a meaningful impact on patients' lives and public health.

• Develop innovative mRNA-based vaccines and therapies
• Address unmet medical needs in infectious diseases, cancer, and rare genetic disorders
• Improve global health outcomes through cutting-edge science and technology
• Foster a culture of innovation, integrity, and collaboration in our organization

How CureVac N.V. (CVAC) Works

CureVac N.V. is a biopharmaceutical company that focuses on the development of mRNA-based vaccines and therapeutics. Their innovative platform utilizes messenger RNA (mRNA) technology to trigger an immune response in the body, leading to the production of specific proteins that can help prevent or treat diseases.

Important aspects of how CureVac N.V. works:

• Messenger RNA Technology: CureVac's approach involves using mRNA to instruct cells in the body to produce proteins that can stimulate an immune response. This technology has the potential to be faster and more adaptable than traditional vaccine development methods.
• Vaccine Development: The company is involved in researching and developing mRNA-based vaccines for a wide range of diseases, including infectious diseases, cancer, and rare genetic disorders. Their pipeline includes candidates for COVID-19, rabies, and influenza.
• Collaborations and Partnerships: CureVac collaborates with various organizations, including government agencies, academic institutions, and pharmaceutical companies, to further develop and advance their mRNA technology. They have partnerships with organizations like the Bill & Melinda Gates Foundation and GlaxoSmithKline.
• Manufacturing and Production: CureVac has established manufacturing facilities to produce mRNA-based vaccines and therapeutics at scale. This infrastructure is crucial for the company's efforts to bring their products to market efficiently and effectively.
• Clinical Trials: Like any biopharmaceutical company, CureVac conducts rigorous clinical trials to evaluate the safety and efficacy of their mRNA-based products. These trials are essential for obtaining regulatory approval and bringing new treatments to patients.
• Regulatory Approval: CureVac works closely with regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to seek approval for their mRNA-based vaccines and therapies. Regulatory approval is necessary before these products can be marketed and distributed to the public.

How CureVac N.V. (CVAC) Makes Money

CureVac N.V. (CVAC) is a biopharmaceutical company that focuses on developing mRNA-based vaccines and therapeutics. The company generates revenue through the following key ways:

• Milestone Payments: CureVac receives milestone payments from collaborations and partnerships with other pharmaceutical companies. These payments are typically tied to the achievement of specific development, regulatory, or commercialization milestones.
• Research Collaborations: The company collaborates with other biopharmaceutical companies, research institutions, and government agencies to develop mRNA-based therapies. These collaborations often involve upfront payments, research funding, and potential royalties on any successful products that result from the partnership.
• License Agreements: CureVac enters into license agreements with other companies to grant them the rights to use its mRNA technology for specific therapeutic applications. In exchange, CureVac receives upfront payments, milestone payments, and royalties on any products that are developed using its technology.
• Product Sales: As CureVac continues to advance its mRNA-based vaccines and therapeutics through clinical development, the company may eventually generate revenue from the sale of these products to healthcare providers, governments, and other customers.
• Government Funding: CureVac may also receive government funding through grants, contracts, or subsidies to support its research and development activities. This funding can help offset some of the costs associated with developing new therapies.